Filing Flows › Titan International (TWI) › Q2 2026 › vs Q2 2025
Titan International (TWI) Q2 2026 vs Q2 2025 (year over year)
Titan International's revenue rose $23.9M (+5%) from $461M in Q2 2025 to $485M in Q2 2026. Gross margin 15.5% against 15.0% (+0.4 pts).
Titan International, Q2 2026: revenue $485M (+5% year over year), operating margin 2.7%, net earnings $5.8M, operating cash flow $39.1M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 15.5% | 15.0% | +0.4 pts |
| Operating margin | 2.7% | 2.2% | +0.5 pts |
| Net margin | 1.2% | -1.0% | +2.2 pts |
| Free cash flow margin | 5.4% | 0.9% | +4.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $485M | $461M | $23.9M | +5% |
| Gross profit | $74.9M | $69.3M | $5.7M | +8% |
| Cost of revenue | $410M | $392M | $18.3M | +5% |
| Operating profit | $13.3M | $10.2M | $3.2M | +31% |
| Operating expenses | $61.6M | $59.1M | $2.5M | +4% |
| Pre-tax earnings | $6.3M | $1.1M | $5.2M | +483% |
| Other expense, net | $7.0M | $9.1M | −$2.1M | -23% |
| Research & development | $5.4M | $4.3M | $1.1M | +24% |
| SG&A | $52.7M | $52.4M | $369K | +0.7% |
| Other operating costs | $3.5M | $2.4M | $1.1M | +44% |
| Income tax benefit | $4K | −$4.7M | $4.7M | — |
| Net earnings | $5.8M | −$4.5M | $10.3M | — |
| Minority interests | $576K | $941K | −$365K | -39% |
| Depreciation & amortization | $17.2M | $16.6M | $597K | +4% |
| Share-based compensation | $1.2M | $1.4M | −$183K | -13% |
| Working capital & other | $14.9M | $831K | $14.1M | 18× |
| Operating cash flow | $39.1M | $14.3M | $24.8M | +174% |
| Free cash flow (company-reported) | $26.4M | $4.2M | $22.2M | +526% |
| Capital expenditures | $12.8M | $10.1M | $2.7M | +26% |
Questions
How much did Titan International's revenue grow year over year in Q2 2026?
Titan International's revenue rose $23.9M (+5%) from $461M in Q2 2025 to $485M in Q2 2026. Gross margin 15.5% against 15.0% (+0.4 pts).